Circulating Plasma miRNA-548L as Novel Predictive Biomarker of Radiotherapy-Induced Severe Oral Mucositis in Patients with Laryngeal Cancer
Genes · 18.05.2026 · 17 (5) · 578
DOI: 10.3390/genes17050578 ↗Kurz gefasst
Fachartikel in der Zeitschrift Genes, online erschienen am 18.05.2026. Verfasst von Marcin Mazurek und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Human Physiology of the Chair of Preclinical Sciences, Medical University of Lublin, 20-080 Lublin, Poland. Hauptthemen laut MEDLINE: Stomatitis, MicroRNAs, Laryngeal Neoplasms, Radiation Injuries. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical University of Lublin.
Abstract (Originalsprache)
Background/Objectives: Oral mucositis (OM) is a common complication in laryngeal cancer (LC), during radiotherapy (RT), significantly affecting patient outcomes. Identifying sensitive biomarkers to predict OM severity is therefore crucial. MicroRNAs, which regulate inflammatory pathways involved in OM, are promising candidates. This retrospective study aimed to evaluate plasma miRNA-548L as a predictive biomarker for the occurrence and severity of OM in LC patients undergoing RT.
Methods
The expression levels of the selected miRNAs were analyzed in plasma samples obtained from 76 LC patients prior to the initiation of RT. Bioinformatics analyses were performed to identify molecular pathways regulated by miRNA-548L and their potential link to the pathogenesis of OM.
Results
Significantly decreased levels of the studied miRNA were observed in the plasma of LC patients who developed severe OM after the IVth (p < 0.001), Vth (p = 0.039), VIth (p < 0.001), and VIIth (p < 0.001) cycles of RT. Additionally, the expression of miRNA-548L enabled reliable differentiation between patients who developed severe OM during the IVth (AUC = 0.81, p < 0.001), Vth (AUC = 0.77, p < 0.001), VIth (AUC = 0.82, p < 0.001), and VIIth (AUC = 0.86, p < 0.001) weeks of treatment. Importantly, lower expression of miRNA-548L (HR = 3.12; p = 0.010) was significantly associated with shorter median overall survival (OS).
Conclusions
Pretreatment plasma miRNA-548L shows potential as a biomarker for predicting severe OM in LC patients undergoing RT. Notably, reduced miRNA-548L expression is associated with shorter OS and may help stratify patients by OM severity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Human Physiology of the Chair of Preclinical Sciences, Medical University of Lublin, 20-080 Lublin, Poland.
- Department of Radiotherapy, St. John of Dukla Lublin Region Cancer Center, 20-090 Lublin, Poland.
ORCID-Profile: Marcin Mazurek, Tomasz Powrózek
Förderung
- Medical University of Lublin
Zitieren
APA
Mazurek, M., Brzozowska, A., Małecka-Massalska, T., & Powrózek, T. (2026). Circulating Plasma miRNA-548L as Novel Predictive Biomarker of Radiotherapy-Induced Severe Oral Mucositis in Patients with Laryngeal Cancer. Genes, 17(5), 578. https://doi.org/10.3390/genes17050578
Vancouver
Mazurek M, Brzozowska A, Małecka-Massalska T, Powrózek T. Circulating Plasma miRNA-548L as Novel Predictive Biomarker of Radiotherapy-Induced Severe Oral Mucositis in Patients with Laryngeal Cancer. Genes. 2026;17(5):578. doi:10.3390/genes17050578
BibTeX
@article{Mazurek2026,
author = {Mazurek, Marcin and Brzozowska, Anna and Małecka-Massalska, Teresa and Powrózek, Tomasz},
title = {Circulating Plasma miRNA-548L as Novel Predictive Biomarker of Radiotherapy-Induced Severe Oral Mucositis in Patients with Laryngeal Cancer},
journal = {Genes},
year = {2026},
volume = {17},
number = {5},
pages = {578},
doi = {10.3390/genes17050578}
}
EUVIMED